TNFRSF17 and Parkinson disease: Neurocognitive and hypokinetic movement disorders (parkinsonisms) after anti-BCMA CAR-T cell infusion are novel emergence cell therapy-related adverse events and are likely caused by an autologous immune attack against BCMA-expressing neurons and astrocytes in the caudate nucleus [116].